AstraZeneca PLC Director/PDMR Shareholding (7145W)

TIDMAZN

RNS Number : 7145W

AstraZeneca PLC

14 December 2023

14 December 2023 15:00 GMT

Transaction by Person Discharging Managerial Responsibilities

AstraZeneca PLC (the Company) announces Anna Manz, Non-Executive Director of the Company, purchased 487 of the Company's ordinary shares of $0.25 each (Ordinary Shares) on 12 December 2023.

Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation (since it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018).

 
      Details of the person discharging managerial responsibilities 
  1    / person closely associated 
 a)   Name                         Anna Manz 
     ---------------------------  -------------------------------------- 
      Reason for the notification 
  2 
     ------------------------------------------------------------------- 
 a)   Position/status              Non-Executive Director 
     ---------------------------  -------------------------------------- 
 b)   Initial notification         Initial notification 
       /Amendment 
     ---------------------------  -------------------------------------- 
      Details of the issuer, emission allowance market participant, 
  3    auction platform, auctioneer or auction monitor 
     ------------------------------------------------------------------- 
 a)   Name                         AstraZeneca PLC 
     ---------------------------  -------------------------------------- 
 b)   LEI                          PY6ZZQWO2IZFZC3IOL08 
     ---------------------------  -------------------------------------- 
      Details of the transaction(s): section to be repeated 
  4    for (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     ------------------------------------------------------------------- 
 a)   Description of the           Ordinary Shares of US$0.25 each in 
       financial instrument,        AstraZeneca PLC 
       type of instrument 
 
       Identification code          GB0009895292 
     ---------------------------  -------------------------------------- 
 b)   Nature of the transaction    Purchase of AstraZeneca PLC Ordinary 
                                    Shares of US$0.25 
     ---------------------------  -------------------------------------- 
 c)   Price(s) and volume(s)         Price(s)       Volume(s) 
                                       GBP101.8956         487 
                                                    ---------- 
     ---------------------------  -------------------------------------- 
 d)   Aggregated information       Not applicable - single transaction 
 
 
       - Aggregated volume 
 
 
       - Price 
     ---------------------------  -------------------------------------- 
 e)   Date of the transaction      12 December 2023 
     ---------------------------  -------------------------------------- 
 f)   Place of the transaction     LON 
     ---------------------------  -------------------------------------- 
 

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca .

Contacts

For details on how to contact the Investor Relations Team, please click here . For Media contacts, click here .

Adrian Kemp

Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHUOARRORUUAUA

(END) Dow Jones Newswires

December 14, 2023 10:00 ET (15:00 GMT)